Results 31 to 40 of about 141,925 (244)

Biofabrication approaches and regulatory framework of metastatic tumor-on-a-chip models for precision oncology. [PDF]

open access: yesMed Res Rev, 2022
AbstractThe complexity of the tumor microenvironment (TME) together with the development of the metastatic process are the main reasons for the failure of conventional anticancer treatment. In recent years, there is an increasing need to advance toward advanced in vitro models of cancer mimicking TME and simulating metastasis to understand the ...
Nieto D   +5 more
europepmc   +5 more sources

Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance

open access: yesNano Convergence, 2021
Recent developments of organoids engineering and organ-on-a-chip microfluidic technologies have enabled the recapitulation of the major functions and architectures of microscale human tissue, including tumor pathophysiology.
Jungeun Lim   +4 more
doaj   +1 more source

Recent Advances of Organ-on-a-Chip in Cancer Modeling Research

open access: yesBiosensors, 2022
Although many studies have focused on oncology and therapeutics in cancer, cancer remains one of the leading causes of death worldwide. Due to the unclear molecular mechanism and complex in vivo microenvironment of tumors, it is challenging to reveal the
Xingxing Liu   +10 more
doaj   +1 more source

Colorectal tumor-on-a-chip system: A 3D tool for precision onco-nanomedicine. [PDF]

open access: yesSci Adv, 2019
This colorectal tumor-on-chip model is an original and reliable platform for high-throughput drug screening and genetic expression.
Carvalho MR   +7 more
europepmc   +4 more sources

Research progress and future perspectives of tumor organoid [PDF]

open access: yesZhongguo aizheng zazhi
Tumor organoids, derived from tumor tissues, are three-dimensional structures created in vitro to mimic in vivo tumor growth. They possess comparable genetic lineage and pathological characteristics to the original tumor, making them a promising research
XIAO Yi, WU Ming, YAO Gang
doaj   +3 more sources

Bioprinting and its Use in Tumor-On-A-Chip Technology for Cancer Drug Screening: A Review. [PDF]

open access: yesInt J Bioprint, 2022
The rising global incidence of cancer and high attrition rates of anticancer drugs make it imperative to design novel screening platforms to increase the success rate of chemotherapeutic agents. Advances in cell culture models from two-dimensional to three-dimensional platforms, along with microfluidics, have resulted in the creation of tumor-on-a-chip
Fang L, Liu Y, Qiu J, Wan W.
europepmc   +3 more sources

Applications of Microfluidics and Organ-on-a-Chip in Cancer Research

open access: yesBiosensors, 2022
Taking the life of nearly 10 million people annually, cancer has become one of the major causes of mortality worldwide and a hot topic for researchers to find innovative approaches to demystify the disease and drug development.
Sagar Regmi   +3 more
doaj   +1 more source

3D Tumor Models and Their Use for the Testing of Immunotherapies

open access: yesFrontiers in Immunology, 2020
Over the past decade, immunotherapy has become a powerful and evident tool in the fight against cancers. Notably, the rise of checkpoint blockade using monoclonal antibodies (anti-CTLA4, anti-PD1) to avoid interaction between inhibitory molecules allowed
Nicolas Boucherit   +2 more
doaj   +1 more source

Advances in analytical microfluidic workflows for differential cancer diagnosis

open access: yesNano Select, 2023
Early detection and functional analysis of circulating tumor cells (CTCs) in liquid biopsy rather than counting them offer great promise as physicians can improve differential diagnosis for second‐ or third‐line treatment beyond today's genotype ...
Morteza Hasanzadeh Kafshgari   +1 more
doaj   +1 more source

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy

open access: yeseLife, 2020
Programmed cell death protein-1 (PD-1) checkpoint immunotherapy efficacy remains unpredictable in glioblastoma (GBM) patients due to the genetic heterogeneity and immunosuppressive tumor microenvironments.
Xin Cui   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy